Efficacy and Safety of Ion Channel Modulators in Painful Diabetic Neuropathy
Authors' conclusion
Ion channel modulators, especially calcium channel blockers and sodium channel antagonists, have favourable safety profiles and beneficial effects on reducing pain and improving the quality of life of patients with PDN.
Study context
- Population
- Patients with painful diabetic neuropathy (PDN)
- Participants
- 6,611 patients36 randomized controlled trials (RCTs)
- Comparison
- Ion channel modulators vs placebo
- Outcome
- Pain score
Methodological detailsPRISMA
- PRISMA
Pooled result
As reported in the abstract
- Ion channel modulators, particularly calcium channel blockers and sodium channel antagonists, significantly reduced pain vs placebo
- Effects of TRPA1 and P2X3 antagonists did not differ significantly from control
Further pooled results
- Calcium and sodium channel blockers significantly reduced visual analog scale (VAS) and sleep interference scores, improved patient global impression of change (PGIC) and increased proportion achieving 30% and 50% pain reduction vs placebo
Safety
- Adverse events mild to moderate and well tolerated
- Higher risk of discontinuation due to adverse events with mirogabalin and oxcarbazepine than other modulators
Original publication
Efficacy and Safety of Ion Channel Modulators in Painful Diabetic Neuropathy. Diabetes Obes Metab. Published 8 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →